Abstract: Objective To investigate the effects of oral dydrogesterone for luteal phase support after frozen embryo transfer
(FET) cycles on the clinical outcomes. Methods A total of 1643 FET cycles in our center between January, 2010 and September,
2011 were analyzed. The patients were divided into group A with natural-cycle FET and group B with hormone replacement
cycle (HRT-FET). The two groups were further divided into two subgroups to receive oral dydrogesterone (groups AI and BI,
n=358 and 185, respectively) or intramuscular progesterone with progynova (groups AII and BII, n=634 and 466, respectively)
as luteal phase support. The clinical pregnancy rates, implantation rates, early miscarriage rates, ectopic pregnancy rates,
ongoing pregnancy rates and delivery rates were compared between the subgroups. Results There were no significant
differences in the clinical outcomes between the patients receiving dydrogesterone and intramuscular progesterone as luteal
phase support in either natural-cycle FET or HRT FET (P>0.05). Conclusion In the FET cycles, oral dydrogesterone tablets for
luteal support can achieve good clinical outcomes comparable with those by intramuscular progesterone and serves as a good
alternative for luteal phase support.